New Mexico Cancer Research Alliance
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, New Mexico Cancer Research Alliance sits in the top decile of US sponsors by registered trial count (#314 of 15,742 sponsors by registered trial count).
New Mexico Cancer Research Alliance: 66 sponsored US clinical trials, 4 recruiting.
New Mexico Cancer Research Alliance sponsors 66 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 34 completed. 3 of these trials are in Phase 3-4 (later-stage) and 34 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ovarian Cancer, with 4 trials.
Top-decile sponsor footprint
New Mexico Cancer Research Alliance ranks in the top decile of sponsors by registered trial count (#314 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
34 of 59 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (57.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
66 total, page 1 of 2
Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial
NCT07436793
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
NCT06207864
Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer
NCT03977402
Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
NCT03943316
Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors
NCT06260332
Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging
NCT03568448
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
NCT02571725
Food Insecurity in Oncology
NCT05176743
Enhancing Cancer Prevention and Control Pathways-Native Health Initiative
NCT04259762
Breast Cancer Screening for Underserved Women: Comparing Outcomes and Lowering Recall Rates With 3D- vs. 2D-mammography
NCT03979729
Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses
NCT02580981
Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel
NCT01821833
Whole Brain Radiation Using IMRT for Patients With Brain Metastases
NCT02753790
Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
NCT02470299
Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer
NCT03983538
Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
NCT02147418
Genome Sequencing of Human Cancer Tissues
NCT02105545
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
NCT01889420
Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells
NCT01765803
A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
NCT01542047
IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors
NCT01746810
INST 1204: PIK3CA Mutations as Biomarkers for Metastasis in Colon Cancer
NCT03951389
Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
NCT01607554
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT01670799
Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC
NCT03953443
Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck
NCT01275183
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
NCT01202890
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
NCT01100242
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
NCT01009203
Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors
NCT01806350
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
NCT00996346
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
NCT01032850
Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
NCT01011075
Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
NCT01009515
Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver
NCT01030757
Comparison of Standard of Care or Treatment on Protocol
NCT01010334
Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
NCT00996827
The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure
NCT00832533
Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers
NCT00832871
Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight
NCT00832520
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
NCT00871169
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma
NCT00947739
Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer
NCT00809458
Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
NCT00996060
A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies
NCT00996515
Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung
NCT00832780
Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
NCT00832637
Observational Study of Best Supportive Care With or Without Surgery, Chemo or Radiotherapy in Pts With Carcinoma of Lung
NCT00822016
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
NCT00945139
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
NCT00659269
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 17 |
| Phase 2 | 17 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the New Mexico Cancer Research Alliance pipeline
4 recruiting of 66 indexed (6% open); 34 completed (52%).
Phase mix: 3 late (III/IV) vs 34 early (I/II) (early-phase heavy).
Top condition: Ovarian Cancer (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
New Mexico Cancer Research Alliance: open-pipeline peers nationwide
Peers matched on 66 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
New Mexico Cancer Research Alliance sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 66 trials (± recruiting share)
- Alkermes · 66 trials · 9% recruiting
- Cornell University · 66 trials · 15% recruiting
- University of Kansas · 66 trials · 8% recruiting
- Prisma Health-Upstate · 67 trials · 9% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Tufts University · 6% recruiting · 163 trials
- BioDelivery Sciences International · 6% recruiting · 17 trials
- Colgate Palmolive · 6% recruiting · 51 trials
- Durham VA Medical Center · 6% recruiting · 17 trials
Related
What to do with this New Mexico Cancer Research Alliance page
66 registered trials is a research-attention snapshot, not an endorsement of New Mexico Cancer Research Alliance or any single study.
- 4 of New Mexico Cancer Research Alliance's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ovarian Cancer is the condition New Mexico Cancer Research Alliance studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ovarian Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
New Mexico Cancer Research Alliance pipeline card: 66 registered trials from official public datasets.Report a data error.